<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Secretin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Secretin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Secretin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10259" href="/d/html/10259.html" rel="external">see "Secretin: Drug information"</a> and <a class="drug drug_patient" data-topicid="11861" href="/d/html/11861.html" rel="external">see "Secretin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F220255"><span class="drugH1">Brand Names: US</span>
<ul>
<li>ChiRhoStim;</li>
<li>SecreFlo</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1062048"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Diagnostic Agent, Gastrinoma (Zollinger-Ellison Syndrome)</span>;</li>
<li>
<span class="list-set-name">Diagnostic Agent, Pancreatic Exocrine Insufficiency</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812552"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dbc15c41-8c05-451c-aeb7-64340f89380f">Diagnostic agent for gastrinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic agent for gastrinoma (Zollinger-Ellison):</b> Limited data available: Adolescents ≥15 years: IV: 0.4 mcg/kg as single dose over 1 minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17108779']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17108779'])">Ref</a></span>). Dosing based on experience with the porcine product; a conversion of 1 unit = 0.2 mcg of human synthetic product has been suggested by the manufacturer.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3e0722c9-60c8-435b-8ce7-d6aa667786d1">Diagnostic agent for pancreatic function</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic agent for pancreatic function:</b> Limited data available: Infants, Children, and Adolescents: IV: 0.2 mcg/kg as single dose over 1 minute; maximum dose: 16 mcg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27400258','lexi-content-ref-28693787']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27400258','lexi-content-ref-28693787'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f943a024-bf6f-4e07-b1ff-3743676d0de4">Facilitation of endoscopic retrograde cholangiopancreatography/magnetic resonance cholangiopancreatography visualization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Facilitation of endoscopic retrograde cholangiopancreatography/magnetic resonance cholangiopancreatography visualization:</b> Limited data available: Infants, Children, and Adolescents: IV: 0.2 mcg/kg as a single dose over 1 minute; maximum dose: 16 mcg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17999059','lexi-content-ref-32023119','lexi-content-ref-23184093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17999059','lexi-content-ref-32023119','lexi-content-ref-23184093'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729828"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F52729829"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F220257"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10259" href="/d/html/10259.html" rel="external">see "Secretin: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;display:inline">
<b>Note:</b> Prior to injection, administer an IV dose of 0.2 mcg to test for possible allergy; if no sign of allergy after 1 minute, may administer the full diagnostic dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a6dfa052-e31e-4011-9893-1ab2a7e4e23b">Diagnostic aid, gastrinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic aid, gastrinoma (Zollinger-Ellison syndrome):</b>
<b>IV:</b> 0.4 mcg/kg as a single dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c0ac560d-89d9-4713-bfd8-43894a68953b">Diagnostic aid, pancreatic exocrine dysfunction or endoscopic retrograde cholangiopancreatography</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic aid, pancreatic exocrine dysfunction or endoscopic retrograde cholangiopancreatography:</b>
<b>IV:</b> 0.2 mcg/kg as a single dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990750"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988133"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F220230"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Gastrointestinal: Nausea (≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, decreased blood pressure, flushing, weak pulse</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, pallor, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, abdominal distress, bloating, burning sensation of gastrointestinal tract, diarrhea, hunger, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity angiitis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, fatigue, headache, numbness of extremities, seizure-like activity, tingling of extremities</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Oxygen saturation decreased, respiratory distress</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F220243"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Use during episodes of acute pancreatitis.</p></div>
<div class="block war drugH1Div" id="F220227"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Allergic reactions: A test dose is recommended prior to administering the full diagnostic dose due to the potential for allergic reactions, particularly in patients with a history of atopic allergy and/or asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Patients with hepatic impairment may be hyperresponsive to secretin stimulation, which may mask the presence of coexisting pancreatic disease. Consider additional testing and clinical assessments to aid in diagnosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Inflammatory bowel disease: Patients who have inflammatory bowel disease may be hyporesponsive to secretin stimulation; secretin test may falsely suggest pancreatic disease. Consider additional testing and clinical assessments to aid in diagnosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Vagotomy: Patients who have undergone vagotomy may be hyporesponsive to secretin stimulation; secretin test may falsely suggest pancreatic disease. Consider additional testing and clinical assessments to aid in diagnosis.</p></div>
<div class="block foc drugH1Div" id="F220238"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SecreFlo: 16 mcg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ChiRhoStim: 16 mcg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F220223"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323825"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (ChiRhoStim Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">16 mcg (per each): $756.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (SecreFlo Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">16 mcg (per each): $510.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52613842"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Administer by direct IV injection slowly over 1 minute.</p></div>
<div class="block adm drugH1Div" id="F220240"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer by IV injection over 1 minute. A test dose is recommended prior to administering the full diagnostic dose.</p></div>
<div class="block sts drugH1Div" id="F220251"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Prior to reconstitution, store at -20°C (-4°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53568789"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Stimulation of gastrin secretion to aid in the diagnosis of gastrinoma (Zollinger-Ellison syndrome); stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction (chronic pancreatitis); facilitation of endoscopic retrograde cholangiopancreatography (ERCP) visualization (All indications: FDA approved in adults).</p></div>
<div class="block cyt drugH1Div" id="F13300032"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F220231"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Histamine H2 Receptor Antagonists: May diminish the diagnostic effect of Secretin. Specifically, use of H2-Antagonists may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma. Management: Avoid concomitant use of histamine H2-antagonists (H2RAs) and secretin. Discontinue H2RAs at least 2 days prior to secretin administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May diminish the diagnostic effect of Secretin. Specifically, use of PPIs may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma. Management: Avoid concomitant use of PPIs or PCABs and secretin, and discontinue PPI or PCAB several weeks prior to secretin administration, with the duration of separation determined by the specific acid suppressant. See full monograph for details.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F220245"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Patients should fast 12 to 15 hours prior to beginning the test.</p></div>
<div class="block pri drugH1Div" id="F220244"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted.</p></div>
<div class="block mopp drugH1Div" id="F53568791"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs and symptoms of allergic reaction during administration of test dose. Refer to protocols for collection of pancreatic secretion and/or serum gastrin diagnostic samples.</p></div>
<div class="block pha drugH1Div" id="F220226"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Human secretin is a synthetic peptide hormone produced by cells in the duodenum in response to acidification; it stimulates pancreatic ductal cells to secrete pancreas fluid in large volumes that contain bicarbonate; may also work through vagal-vagal neural pathways since stimulation of the efferent vagus nerve stimulates bicarbonate.</p></div>
<div class="block phk drugH1Div" id="F220242"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 2.7 L</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 45 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Clearance: 580.9 ± 51.3 mL/minute</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038825"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Sekretolin diagnos</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Secrelux</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Secretin kabi</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Gaspretin | Secrepan | Secretin eisai</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Sekretolin diagnos</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Sekretolin diagnos</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Secrelux | Secrelux unimedic</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Secretolin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-17108779">
<a name="17108779"></a>Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. <i>Medicine (Baltimore)</i>. 2006;85(6):331-364.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secretin-pediatric-drug-information/abstract-text/17108779/pubmed" id="17108779" target="_blank">17108779</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  ChiRhoStim (secretin human injection, powder, lyophilized) [prescribing information]. Burtonsville, MD: ChiRhoClin; July 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17999059">
<a name="17999059"></a>Delaney L, Applegate KE, Karmazyn B, Akisik MF, Jennings SG. MR cholangiopancreatography in children: feasibility, safety, and initial experience. <i>Pediatr Radiol</i>. 2008;38(1):64-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secretin-pediatric-drug-information/abstract-text/17999059/pubmed" id="17999059" target="_blank">17999059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400258">
<a name="27400258"></a>Horvath K, Loveridge-Lenza B, Brenn BR, Del Rosario JF, Molle-Rios Z, He Z. Safety of secretin administration in children. <i>Pancreas</i>. 2016;45(9):1336-1340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secretin-pediatric-drug-information/abstract-text/27400258/pubmed" id="27400258" target="_blank">27400258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32023119">
<a name="32023119"></a>Li Y, Dillman JR, Anton CG, et al. Secretin improves visualization of nondilated pancreatic ducts in children undergoing MRCP. <i>AJR Am J Roentgenol.</i> 2020;214(4):917-922. doi:10.2214/AJR.19.21798<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secretin-pediatric-drug-information/abstract-text/32023119/pubmed" id="32023119" target="_blank">32023119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11328261">
<a name="11328261"></a>Metz DC, Buchanan M, Purich E, et al, “A Randomized Controlled Crossover Study Comparing Synthetic Porcine and Human Secretins With Biologically Derived Porcine Secretin to Diagnose Zollinger-Ellison Syndrome,”<i>Aliment Pharmacol Ther</i>, 2001, 15(5):669-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secretin-pediatric-drug-information/abstract-text/11328261/pubmed" id="11328261" target="_blank">11328261</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  SecreFlo (secretin) [prescribing information]. Hampstead, MD: Bell-More Labs, Inc; May 2005.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23184093">
<a name="23184093"></a>Trout AT, Podberesky DJ, Serai SD, Ren Y, Altaye M, Towbin AJ. Does secretin add value in pediatric magnetic resonance cholangiopancreatography? <i>Pediatr Radiol</i>. 2013;43(4):479-486.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secretin-pediatric-drug-information/abstract-text/23184093/pubmed" id="23184093" target="_blank">23184093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28693787">
<a name="28693787"></a>Trout AT, Wallihan DB, Serai S, Abu-El-Haija M. Secretin-enhanced magnetic resonance cholangiopancreatography for assessing pancreatic secretory function in children. <i>J Pediatr</i>. 2017;188:186-191. doi:10.1016/j.jpeds.2017.06.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secretin-pediatric-drug-information/abstract-text/28693787/pubmed" id="28693787" target="_blank">28693787</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12784 Version 104.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
